Newtyn Management, LLC Adagio Therapeutics, Inc. Transaction History

Newtyn Management, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	N/A	-887,063 Reduced 98.56%	12,937 $42,000
Q4 2022 Feb 14, 2023	BUY	$3.08 - $4.05 $1.69 Million - $2.23 Million	550,000 Added 157.14%	900,000 $2.98 Million
Q3 2022 Nov 14, 2022	SELL	$2.97 - $4.83 $151,098 - $245,726	-50,875 Reduced 12.69%	350,000 $1.1 Million
Q2 2022 Aug 15, 2022	BUY	$2.54 - $4.52 $1.02 Million - $1.81 Million	400,875 New	400,875 $1.32 Million

63.9M

2.3K

2.1K

Ticker ADGI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 108,831,000
Market Cap $505M
Description
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...

Get notified when there are updates to the investment portfolio of Newtyn Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Newtyn Management, LLC with notifications on news.